Ligand id: 9295

Name: emapalumab

Immunopharmacology Comments
Emapalumab is an anti-IFNγ therapy. It is the first drug specifically targeted for the treatment of primary HLH, and represents a major advance in treatment for this ultra-rare syndrome.
Immunopharmacology Disease
Disease X-Refs Comment References
Hemophagocytic lymphohistiocytosis Disease Ontology: DOID:0050120
OMIM: 603552
Orphanet: ORPHA158032
Approved therapy for HLH in adult and pediatric patients (FDA 2018). 1